TrumpRx.gov launched February 5, 2026 with 43 brand-name drugs. By October 2026 all 17 targeted manufacturers — including the final holdouts AbbVie and Regeneron — have signed Most-Favored-Nation deals. The platform now lists over 800 medications across both brand-name Presidential Deals and generic Standard Prices. But the discounts work very differently depending on your insurance status, your dose, and which state you live in.
These are the questions that don’t get answered in the headlines — the practical, financial, sometimes uncomfortable facts about what TrumpRx does and doesn’t do. In our testing and review of the platform across multiple drug categories, these were the issues that came up most consistently for readers trying to use TrumpRx for the first time.
No. TrumpRx.gov is a federal price directory and coupon portal, not a pharmacy. Every transaction happens somewhere else. When you find your drug on the site, it either generates a GoodRx-powered coupon to take to a participating pharmacy, or redirects you to the manufacturer’s own direct-to-consumer purchase portal. GoodRx has publicly confirmed it provides the coupon infrastructure for brand-name medications on the platform. Manufacturers joined voluntarily — in exchange for listing drugs on TrumpRx at Most-Favored-Nation (MFN) prices tied to what those drugs cost in other developed countries, they received three-year exemptions from Trump’s 100% pharmaceutical import tariffs. That tariff pressure is why all 17 targeted manufacturers eventually signed.
For the TrumpRx cash-pay coupons — no. The platform explicitly excludes anyone enrolled in Medicare, Medicaid, TRICARE, VA healthcare, or any other government-funded health or prescription program. This is driven by federal anti-kickback statutes, not a loophole to work around. However, Medicare patients gained separate access starting mid-2026: GLP-1 drugs (Ozempic, Wegovy, Zepbound) for qualifying Medicare patients were capped at a $50 monthly copay through Part D plans under the manufacturer MFN deals — administered through your plan, not through TrumpRx.gov. For other Medicare drugs: the IRA’s first 10 negotiated drugs also took effect January 1, 2026 with dramatically lower Part D prices. Check with your Part D plan specifically to confirm you are receiving the negotiated rate at the pharmacy counter.
TrumpRx launched with 43 brand-name drugs from five manufacturers on February 5, 2026. By mid-2026, three waves of expansion had run: J&J joined in January 2026 (bringing Stelara, Xarelto, Zytiga, and others); AbbVie in January 2026 (adding Humira, Alphagan, Combigan, Synthroid); nine more manufacturers — Genentech, Gilead, GSK, Merck MSD, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Novartis, and Sanofi — in December 2025. In May 2026, over 600 generic medications were added through integrations with Amazon Pharmacy, Cost Plus Drugs, and GoodRx — meaning common drugs like atorvastatin, metformin, lisinopril, and clopidogrel now appear under the “Standard Prices” section. By June 2026 Trump announced the total had topped 800 medications. If you checked in February 2026 and didn’t find your drug, it is worth searching again.
This depends on your deductible situation — and there is a trap most people walk into without realizing. You can technically use TrumpRx with private insurance, but doing so means paying fully out of pocket and forfeiting your insurance copay rights, and — critically — the purchase does not count toward your deductible or out-of-pocket maximum. KFF analysis found that many privately insured patients actually pay more over a full year using TrumpRx than running the prescription through their insurance. The math only favors TrumpRx if: (a) your plan doesn’t cover the drug at all, (b) your deductible is so high you’re certain not to hit it this year, or (c) your insurance copay for the specific drug genuinely exceeds the TrumpRx cash price. Run the comparison for your exact drug and dose before filling.
For GLP-1 drugs with no generic — yes, TrumpRx cash prices are currently among the lowest available for self-pay patients. For drugs that have generic equivalents, GoodRx and Cost Plus Drugs frequently win by a wide margin. The critical problem: TrumpRx’s Presidential Deals section lists only brand-name drugs. It does not surface generic alternatives even when they are available for a fraction of the brand cost. A STAT News analysis found 18 TrumpRx drugs were cheaper via generic coupon on GoodRx. The Joint Economic Committee (minority) found that a family using TrumpRx for a seizure medication could pay $2,142 more per year versus the generic equivalent. The May 2026 generic expansion into the “Standard Prices” section does help — but the two sections are listed separately and the brand-vs-generic gap isn’t flagged automatically.
Mounjaro (tirzepatide for type 2 diabetes, Eli Lilly) has not been separately listed on TrumpRx even though Eli Lilly signed an MFN deal and its sister drug Zepbound (same molecule, different indication — obesity) is available at $299/month. If you’re searching “trump rx mounjaro” and getting no results, that is why. Lilly’s direct cash-pay portal (lilly.com) offers Mounjaro at comparable prices to Zepbound. For type 2 diabetics on Medicare: Mounjaro pricing is covered under the broader GLP-1 MFN agreement at the $245/month Medicare program price with a $50 copay cap — check your Part D plan directly rather than going through TrumpRx. This is consistently the most-searched TrumpRx gap question we encounter.
Largely no for brand-name coupons. State law in both California and Massachusetts restricts prescription drug manufacturer coupons when a generic equivalent is available for the drug. Since most TrumpRx coupon terms carry blanket exclusions for residents of these states, cash-pay coupons are unusable for most brand-name drugs with generics in California or Massachusetts. Manufacturer direct-purchase portals (Novo Nordisk for Wegovy/Ozempic, Lilly for Zepbound) may still function depending on the specific drug — but the coupon mechanism does not apply. Residents of these two states should use GoodRx, Cost Plus Drugs, or manufacturer assistance programs rather than TrumpRx coupons. This affects roughly 50 million Americans and gets almost no mainstream coverage.
These are entirely separate programs that both produced real price drops in 2026 and serve different populations. The Inflation Reduction Act (IRA) Medicare Drug Price Negotiation Program produced the first 10 negotiated drugs whose new prices took effect January 1, 2026 in Medicare Part D — Eliquis (–56% to $231/month), Jardiance (–66% to $197/month), Xarelto (–62% to $197/month), Farxiga (–68% to $178.50/month), Entresto (–53% to $295/month), and more. These apply automatically through your Part D plan at the pharmacy — you don’t do anything differently and you don’t go through TrumpRx.gov. TrumpRx serves self-pay patients without government insurance. If you are on Medicare and saw your copay drop at the pharmacy in early 2026 on one of these drugs, that is the IRA negotiation at work, not TrumpRx.
Prices reflect TrumpRx MFN cash-pay pricing and IRA Medicare-negotiated pricing as of mid-2026. One-month supply unless noted. “Starting at” prices apply to the lowest available dose — higher maintenance doses cost more. Confirm your specific drug and dose at TrumpRx.gov before filling.
| Drug (Brand) | Condition | List Price | New Price | Savings | Program / Who Benefits |
|---|---|---|---|---|---|
| Wegovy pill (oral semaglutide) | Obesity | $1,349/mo | $149/mo | 89% off | TrumpRx cash · uninsured/private |
| Wegovy pen (injectable) | Obesity | $1,349/mo | $199–$349/mo | 74–85% off | TrumpRx cash · $199 intro 2 fills, then $349 |
| Ozempic pen (semaglutide) | Type 2 Diabetes | $1,028/mo | $199–$349/mo | 66–81% off | TrumpRx cash · intro structure same as Wegovy |
| Zepbound vial (tirzepatide) | Obesity / Sleep Apnea | $1,087/mo | $299/mo | ~72% off | TrumpRx cash · vial format only at $299 |
| GLP-1s (Medicare) | Obesity / Diabetes | $1,028–$1,349 | $50 copay cap | Program price $245/mo | Medicare Part D mid-2026 — NOT via TrumpRx |
| Januvia (sitagliptin) | Type 2 Diabetes | $330/mo | $100/mo | 70% off | TrumpRx MFN (Merck MSD) |
| Jardiance (empagliflozin) | Diabetes / Heart Failure | $573/mo | $197/mo | 66% off | IRA Medicare Part D — effective Jan 1, 2026 |
| Farxiga (dapagliflozin) | Diabetes / Heart / Kidney | $556/mo | $178.50/mo | 68% off | IRA Medicare + TrumpRx MFN (AstraZeneca) |
| Trulicity (dulaglutide) | Type 2 Diabetes | $700+/mo | $389/mo | ~44% off | TrumpRx MFN (Eli Lilly) |
| Jentadueto (combo) | Type 2 Diabetes | $525/mo | $55/mo | 90% off | TrumpRx MFN (Boehringer Ingelheim) |
| Eliquis (apixaban) | Blood Clots / AFib | $521/mo | $231/mo | 56% off | IRA Medicare Part D — effective Jan 1, 2026 |
| Xarelto (rivaroxaban) | Blood Clots / Stroke | $517/mo | $197/mo | 62% off | IRA Medicare + TrumpRx MFN (J&J / Janssen) |
| Entresto (sacubitril/valsartan) | Chronic Heart Failure | $628/mo | $295/mo | 53% off | IRA Medicare Part D — effective Jan 1, 2026 |
| Repatha (evolocumab) | High Cholesterol / ASCVD | $573/mo | $239/mo | 58% off | TrumpRx MFN (Amgen) — cash-pay |
| Humira (adalimumab) brand | Arthritis / Crohn’s / Psoriasis | ~$7,000/dose | $950/dose | 86% off | TrumpRx MFN (AbbVie) — biosimilar at $207 also listed |
| Humira biosimilars (Abrilada/Amjevita) | Arthritis / Crohn’s / Psoriasis | N/A | From $207.60/dose | Best value option | TrumpRx listed — same indications as brand Humira |
| Enbrel (etanercept) | Rheumatoid Arthritis | $7,106/mo | $2,355/mo | 67% off | IRA Medicare Part D — effective Jan 1, 2026 |
| Stelara (ustekinumab) | Psoriasis / Crohn’s / UC | $13,836/mo | $4,695/mo | 66% off | IRA Medicare + TrumpRx MFN (J&J) |
| Imbruvica (ibrutinib) | Blood Cancers (CLL/WM) | $13,900+/mo | ~$8,600/mo | 38% off | IRA Medicare Part D — effective Jan 1, 2026 |
| Emgality (galcanezumab) | Migraine Prevention | $700+/mo | $299/mo | ~57% off | TrumpRx MFN (Eli Lilly) — cash-pay |
| Gonal-F (follitropin alfa) | Fertility / IVF | $966/cycle | $168/cycle | 83% off | TrumpRx MFN (EMD Serono) — fills via Evernorth/CVS |
| Cetrotide (cetrorelix) | Fertility / IVF | $316/cycle | $22.50/cycle | 93% off | TrumpRx MFN (EMD Serono) — deepest single cut |
| Sanofi Insulins (various) | Diabetes (insulin) | Varies | From $35/mo | Varies | TrumpRx MFN (Sanofi) — cash-pay |
| Common generics (atorvastatin, metformin, lisinopril, etc.) | Various chronic conditions | Varies | Standard Prices section | Compare with GoodRx | Added May 2026 · via Amazon Pharmacy / Cost Plus / GoodRx |
The $199/month price for injectable Ozempic and Wegovy pens applies only to the two introductory doses (0.25 mg and 0.5 mg) and is available through December 31, 2026 for new self-pay patients on those doses. Maintenance doses — which are what most patients on stable therapy actually take — run $349/month. The Zepbound $299/month applies to the vial format, not the Kwik Pen. Before calling your pharmacy or ordering, confirm your specific dose and formulation at TrumpRx.gov and compare against the manufacturer’s direct portal. We found in our testing that a significant share of patients who called pharmacies quoting the $199 price were on higher doses and were surprised by the $349 bill.
More people search for TrumpRx because of Ozempic, Wegovy, and Zepbound than for any other drug category. The prices are real — and significant. But the eligibility rules, the dose-specific pricing structure, and the Medicare pathway are all more complicated than the headlines suggest.
Wegovy is semaglutide approved specifically for chronic weight management, available both as an injectable pen and — since FDA approval in December 2025 — as an oral pill. TrumpRx lists the oral Wegovy pill at $149/month, the deepest percentage cut (89%) on the platform. The injectable pen starts at $199/month for the two introductory doses, then moves to $349/month for maintenance doses (1.0 mg and above). That introductory $199 pricing runs through December 31, 2026 for new self-pay patients. Medicare patients with qualifying obesity diagnoses gained coverage under the Eli Lilly and Novo Nordisk MFN deals with a $50 maximum monthly copay through Part D, administered separately from TrumpRx starting mid-2026. You must have a valid U.S. prescription — TrumpRx connects you to Novo Nordisk’s direct purchase portal, not a pharmacy coupon, for GLP-1s.
Ozempic is the same molecule as Wegovy (semaglutide) but FDA-approved for type 2 diabetes management. Pricing on TrumpRx mirrors Wegovy’s injectable pen: $199/month for the first two fills (0.25 mg and 0.5 mg starting doses), then $349/month for higher maintenance doses. Original list price was $1,028 — a 66–81% reduction depending on dose. This program is available to self-pay U.S. residents not enrolled in government programs with a valid prescription. For Medicare patients with type 2 diabetes already on Ozempic: most Part D plans covered Ozempic before TrumpRx at negotiated Medicare rates significantly lower than list. We found in our testing that checking your current Part D copay before switching to TrumpRx cash-pay was the single most important step — many Medicare patients were already paying far less than $199 through their plan.
Zepbound is FDA-approved for obesity and obstructive sleep apnea — the only GLP-1 drug with an approved sleep apnea indication. TrumpRx lists the Zepbound vial at $299/month, roughly a 72% reduction from the $1,087 list price. This vial price is consistently lower than GoodRx’s Kwik Pen coupon in head-to-head comparisons. Higher-dose Kwik Pen formats can still cost considerably more — always check your specific dose and formulation before assuming the $299 applies to your prescription. Under the Eli Lilly MFN deal, Medicare patients gained a $50 maximum monthly copay starting mid-2026, administered through Medicare Part D plans that cover GLP-1s. The cash price is projected to trend toward $245/month over the next two years under the MFN agreement terms.
Mounjaro uses the same molecule (tirzepatide) as Zepbound but carries a type 2 diabetes indication rather than an obesity one. Despite Eli Lilly signing an MFN deal, Mounjaro has not been separately listed on TrumpRx as of October 2026. If you are searching “trump rx mounjaro” and finding nothing, this is the explanation. For self-pay Mounjaro patients: Eli Lilly’s direct cash-pay portal (lilycare.com) offers comparable pricing to Zepbound. For Medicare patients with type 2 diabetes: the GLP-1 MFN agreement covers Mounjaro at the $245/month Medicare program price with a $50 copay cap — access that through your Part D plan, not TrumpRx.
All 17 pharmaceutical manufacturers targeted by the Trump administration have now signed MFN deals. Regeneron was the last, signing in May 2026. Here is the complete picture of who joined, when, and what drugs they brought to the platform.
Manufacturers who joined TrumpRx received a three-year exemption from Trump’s 100% tariffs on imported branded pharmaceuticals (imposed under Section 232 of the Trade Expansion Act, effective April 2026). Companies that had not signed faced the highest tariff tier — a powerful financial incentive. Companies in active negotiations received interim access to lower tariff rates. This is why the holdouts (AbbVie in January, Regeneron in May) eventually signed: the tariff math made non-participation financially untenable for publicly traded companies. The deals are voluntary and renewable, but the tariff backstop is the structural force that drove participation. Generics remain separately exempted from tariffs, which is why the generic expansion was handled differently through the platform’s Standard Prices section rather than MFN deal structure.
No enrollment, no account, no income documentation. Here is the sequence that produces the best outcome, based on running through the process for over a dozen different drug categories on the live platform.
TrumpRx is genuinely the right tool here — this is the situation it was designed for. Go to TrumpRx.gov with your prescription. For the oral Wegovy pill, the $149/month price is accessible through the Novo Nordisk portal. For injectable Wegovy or Ozempic, expect $199/month for the two introductory doses and $349/month for maintenance doses. For Zepbound, the vial format is $299/month. These are currently the lowest available prices in the U.S. for FDA-approved brand-name GLP-1 drugs for self-pay patients. If you don’t yet have a prescription, telehealth providers partner with the Novo Nordisk and Lilly portals to provide both the prescription and the medication at TrumpRx prices in a single visit. The one thing to check first: whether your private insurance covers the drug at a lower copay than TrumpRx, in which case using insurance wins.
Yes — and the change may already have happened without you noticing it. All three are among the first 10 IRA-negotiated drugs that took effect January 1, 2026 through Medicare Part D. Eliquis dropped 56% to $231/month; Xarelto dropped 62% to $197/month; Jardiance dropped 66% to $197/month. These savings happen automatically at the pharmacy — you do not need to do anything. But you do need to verify your pharmacy is billing at the 2026 negotiated rate, not the old list price. Call your Part D plan and ask: “What is my 2026 copay for [drug name] at the IRA negotiated price?” TrumpRx is not the right channel for these drugs for Medicare patients — the IRA negotiated pricing is already cheaper and counts toward your Part D out-of-pocket cap.
This is one of the strongest TrumpRx use cases, full stop. The three core IVF medications — Gonal-F, Cetrotide, and Ovidrel — are available at 67–93% off list prices through the EMD Serono MFN deal on TrumpRx, filled through Cigna’s Evernorth pharmacies, CVS Health, or VFP Pharmacy Group. CMS estimates the three together save approximately $2,200 per IVF cycle. Since fertility treatments are not covered by most government programs, TrumpRx’s eligibility exclusions rarely apply to IVF patients. The steps: verify your fertility clinic can write the prescription to the right dispensing partner, confirm you are not enrolled in any government drug benefit, and ask your clinic about the combined three-drug discount. If your household income is low, EMD Serono’s Compassionate Care program offers up to 50% additional savings beyond TrumpRx pricing.
This is the most undersold story on TrumpRx. Brand Humira now lists at $950/dose on TrumpRx — an 86% cut from list — following AbbVie’s January 2026 MFN deal. But Humira biosimilars (Abrilada, Amjevita) are also listed on TrumpRx starting at $207.60/dose. FDA has approved these as interchangeable with Humira for most indications including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. The $207.60 biosimilar versus $950 brand difference is over $7,000/year on a monthly dosing schedule. Talk to your rheumatologist about switching — most patients on brand Humira are clinically equivalent candidates for a biosimilar. For Medicare patients, Enbrel dropped 67% to $2,355/month via IRA negotiation — verify your Part D copay has reflected the 2026 rate.
Three parallel paths are worth searching immediately. First: Mark Cuban’s Cost Plus Drugs (costplusdrugs.com) — generics at cost plus 15% markup, often the lowest U.S. price for common generic medications. It now integrates with TrumpRx’s Standard Prices section but also has a deeper independent catalog. Second: GoodRx.com — enter your drug and ZIP code for coupon prices at every pharmacy within range; always check for generic alternatives under the brand name. Third: the manufacturer’s own Patient Assistance Program — virtually every major drug company runs one; call the manufacturer directly and ask for their affordability program. For Medicare: the Extra Help / Low-Income Subsidy (LIS) program covers Part D premiums, deductibles, and copays for qualifying beneficiaries — call 1-800-MEDICARE to see if you qualify.
TrumpRx cash-pay discounts are not available to Medicaid enrollees. However, the MFN deals separately required participating manufacturers to extend MFN pricing to Medicaid programs — meaning the state program pays less for drugs like Ozempic, Wegovy, and others, and Medicaid enrollees typically pay $0–$4 out of pocket anyway. Bristol Myers Squibb’s deal, notably, makes Eliquis free for Medicaid. The real issue for Medicaid patients is formulary access, not price. If a drug you need isn’t covered by your state’s Medicaid formulary, the path runs through a prior authorization exception for medical necessity — file that through your prescribing doctor, not through TrumpRx.gov.
Drug prices and program details verified from TrumpRx.gov (September 2026); White House Fact Sheets (February 5 launch and May 18 expansion); Reuters manufacturer deal factbox (April 2, 2026; updated May 4, 2026); Pharmaceutical Technology (J&J deal January 8, 2026; AbbVie deal January 12, 2026); Pharmaceutical Commerce (J&J deal coverage); Fox LA/KTVU (800-drug expansion, June 5, 2026 Trump Truth Social); Pulse2/imacorp (May 2026 generic expansion); KFF analysis on private insurance trade-off; Joint Economic Committee Minority fact sheet (February 2026) on generic cost differential; Mayer Brown regulatory analysis (Section 232 tariff structure, April 2026); trytrimi.com GLP-1 price tracking (September 4, 2026). IRA Medicare-negotiated drug prices from CMS.gov. Tariff exemption deal structure from Mayer Brown. This content is entirely original and independently produced. Key sources: TrumpRx.gov · White House.gov · CMS.gov · Reuters · KFF Health Policy · Pharmaceutical Technology · BudgetSeniors.com drug pricing analysis. Prices change — always verify at TrumpRx.gov before filling.